Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital

Rates of myocardial infarction and stroke in patients initiated on SGLT2-inhibitors versus other glucose-lowering agents in real-world clinical practice: results from the CVD-REAL study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review


  1. Is glucagon-like peptide-1 fully protected by dipeptidyl peptidase 4 inhibitor administration in patients with type 2 diabetes?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Glucose-lowering effects and mechanisms of the bile acid-sequestering resin sevelamer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Cardiovascular biomarkers in clinical studies of type 2 diabetes

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  • Mikhail Kosiborod
  • Kåre I Birkeland
  • Matthew A Cavender
  • Alex Z Fu
  • John P Wilding
  • Kamlesh Khunti
  • Reinhard W Holl
  • Anna Norhammar
  • Marit Eika Jørgensen
  • Eric T Wittbrodt
  • Marcus Thuresson
  • Johan Bodegård
  • Niklas Hammar
  • Peter Fenici
  • CVD-REAL Investigators and Study Group
Vis graf over relationer

The multinational, observational CVD-REAL study recently showed that initiation of sodium-glucose co-transporter-2 inhibitors (SGLT-2i) was associated with significantly lower rates of death and heart failure vs. other glucose-lowering drugs (oGLDs). This sub-analysis of CVD-REAL sought to determine the association between initiation of SGLT-2i vs. oGLDs and rates of myocardial infarction (MI) and stroke. Medical records, claims and national registers from the US, Sweden, Norway and Denmark were used to identify patients with T2D newly initiated on SGLT-2i (canagliflozin, dapagliflozin or empagliflozin) or oGLDs. A non-parsimonious propensity score was developed within each country to predict initiation of SGLT-2i, and patients were matched 1:1 in the treatment groups. Pooled hazard ratios (HR) and 95% CI were generated using Cox regression models. Overall, 205,160 patients were included. In the intent-to treat analysis, over 188,551 and 188,678 person-years follow-up (MI and stroke, respectively), there were 1077 MI and 968 stroke events. Initiation of SGLT-2i vs. oGLD was associated with a modestly lower risk of MI and stroke (MI: HR 0.85, 95%CI 0.72-1.00; P=0.05; Stroke: HR 0.83, 95%CI 0.71-0.97; P=0.02). These findings complement the results of the cardiovascular outcomes trials, and offer additional reassurance in regards to the cardiovascular effects of SGLT-2i, specifically as it relates to ischaemic events.

TidsskriftDiabetes, Obesity and Metabolism
Udgave nummer8
Sider (fra-til)1983-1987
Antal sider4
StatusUdgivet - aug. 2018

ID: 53599497